Search

Your search keyword '"Howard, Matthew A."' showing total 21 results
Start Over Author "Howard, Matthew A." Journal blood
21 results on '"Howard, Matthew A."'

1. Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021

Author

Abdelmagid, Maymona, primary, Al-Kali, Aref, additional, Begna, Kebede H., additional, Hogan, William J., additional, Litzow, Mark R., additional, Mangaonkar, Abhishek A., additional, Patnaik, Mrinal M.M., additional, Elliott, Michelle A, additional, Alkhateeb, Hassan B., additional, Shi, Min, additional, Howard, Matthew, additional, Reichard, Kaaren K., additional, Ketterling, Rhett P., additional, Pardanani, Animesh, additional, Gangat, Naseema, additional, and Tefferi, Ayalew, additional

Published
2022
Full Text
View/download PDF

2. Cell-Type and Allele Specific Distribution of Multiple TET2 Mutations in Two Patients with Chronic Myelomonocytic Leukemia (CMML)

Author

Lasho, Terra, primary, Finke, Christy, additional, Timm, Michael M., additional, Durruthy-Durruthy, Robert, additional, Arribas-Layton, Marc, additional, Patnaik, Mrinal M., additional, Tefferi, Ayalew, additional, Gangat, Naseema, additional, Mangaonkar, Abhishek A., additional, Binder, Moritz, additional, Gaspar Maia, Alexandre, additional, Mohammed Ismail, Wazim, additional, Howard, Matthew T, additional, and Chia, Nicholas, additional

Published
2021
Full Text
View/download PDF

3. Differential Prognostic Impact of IDH1 and IDH2 Mutations in Chronic Myelomonocytic Leukemia

Author

Walsh, Connor M., primary, Hunter, Anthony, additional, Lasho, Terra, additional, Finke, Christy, additional, Komrokji, Rami S., additional, Shah, Mithun V., additional, Tefferi, Ayalew, additional, Mangaonkar, Abhishek A., additional, Howard, Matthew T, additional, Gangat, Naseema, additional, Al-Kali, Aref, additional, Al Ali, Najla, additional, Padron, Eric, additional, and Patnaik, Mrinal M., additional

Published
2021
Full Text
View/download PDF

4. Histopathologic Characterization of Vexas Syndrome

Author

Barouqa, Mohammad I., primary, Ravindran, Aishwarya, additional, Chen, Dong, additional, Oliveira, Jennifer L, additional, Olteanu, Horatiu, additional, Howard, Matthew T, additional, Zheng, Gang, additional, Patnaik, Mrinal M., additional, Begna, Kebede H., additional, Bock, Allison M., additional, Go, Ronald, additional, Koster, Matthew, additional, Kourelis, Taxiarchis, additional, Mangaonkar, Abhishek A., additional, Ryu, Jay, additional, Samec, Matthew, additional, Sartori Valinotti, Julio C., additional, Warrington, Kenneth, additional, and Reichard, Kaaren K., additional

Published
2021
Full Text
View/download PDF

5. Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study

Author

Difilippo, Emma Catherine, primary, Ferrer, Alejandro, additional, Schultz-Rogers, Laura, additional, Gangat, Naseema, additional, Khan, Shakila P, additional, Al-Kali, Aref, additional, Mangaonkar, Abhishek A., additional, Pardanani, Animesh, additional, Elliot, Michelle, additional, Litzow, Mark, additional, Hogan, William J, additional, Wolanskyj, Alexandra P., additional, Nguyen, Phuong L., additional, Reichard, Kaaren K., additional, Howard, Matthew T, additional, King, Rebecca L., additional, Chen, Dong, additional, He, Rong, additional, Viswanatha, David S., additional, Lasho, Terra, additional, Pruthi, Rajiv K., additional, Pichurin, Pavel, additional, Kruisselbrink, Teresa, additional, Lanpher, Brendan, additional, Wylam, Mark E, additional, Oliveira, Jennifer L., additional, Babovic-Vuksanovic, Dusica, additional, Olteanu, Horatiu, additional, and Patnaik, Mrinal M., additional

Published
2020
Full Text
View/download PDF

6. Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients

Author

Li, Marissa, primary, Lasho, Terra, additional, Ferrer, Alejandro, additional, Gangat, Naseema, additional, Al-Kali, Aref, additional, Mangaonkar, Abhishek A., additional, Elliot, Michelle, additional, Litzow, Mark, additional, Hogan, William J, additional, Pardanani, Animesh, additional, Wolanskyj-Spinner, Alexandra, additional, Reichard, Kaaren K., additional, Howard, Matthew T, additional, King, Rebecca L., additional, Shah, Mithun Vinod, additional, Alkhateeb, Hassan B., additional, Begna, Kebede H., additional, Tefferi, Ayalew, additional, Finke, Christy, additional, Binder, Moritz, additional, Olteanu, Horatiu, additional, and Patnaik, Mrinal M., additional

Published
2020
Full Text
View/download PDF

7. Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures

Author

Carr, Ryan M., primary, Lasho, Terra, additional, Marks, David, additional, Tolosa, Ezequiel, additional, Almada, Luciana L, additional, Alver, Bonnie, additional, Binder, Moritz, additional, Safgren, Stephanie, additional, Horn, Isaac, additional, Berger, Kurt, additional, Mangaonkar, Abhishek A, additional, Antelo, Guadalupe Belen, additional, Coltro, Giacomo, additional, Pin, Christopher, additional, Witzig, Thomas E., additional, Robertson, Keith, additional, Howard, Matthew T, additional, Geissler, Klaus, additional, Gangat, Naseema, additional, Tefferi, Ayalew, additional, Pardanani, Animesh, additional, Al-Kali, Aref, additional, Litzow, Mark, additional, Elliott, Michelle A, additional, Kaufmann, Scott H., additional, Fernandez-Zapico, Martin, additional, and Patnaik, Mrinal M, additional

Published
2019
Full Text
View/download PDF

8. Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)

Author

Antelo, Guadalupe Belen, primary, Coltro, Giacomo, additional, Mangaonkar, Abhishek A, additional, Lasho, Terra, additional, Finke, Christy, additional, Carr, Ryan M., additional, Gangat, Naseema, additional, Binder, Moritz, additional, Al-Kali, Aref, additional, Elliott, Michelle A, additional, Howard, Matthew T, additional, King, Rebecca L., additional, Hogan, William J, additional, Litzow, Mark, additional, Pardanani, Animesh, additional, Tefferi, Ayalew, additional, Fernandez-Zapico, Martin, additional, and Patnaik, Mrinal M, additional

Published
2019
Full Text
View/download PDF

9. Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia

Author

Mangaonkar, Abhishek A., primary, Reichard, Kaaren K., additional, Chiu, April, additional, Howard, Matthew T, additional, King, Rebecca L, additional, Carr, Ryan M., additional, Alver, Bonnie M, additional, Robertson, Keith D., additional, Cousin, Margot, additional, Villasboas, Jose C, additional, Fernandez-Zapico, Martin E., additional, Lasho, Terra L., additional, Gangat, Naseema, additional, Al-Kali, Aref, additional, Elliott, Michelle A., additional, Hogan, William J., additional, Litzow, Mark R., additional, Pardanani, Animesh, additional, Solary, Eric, additional, Tefferi, Ayalew, additional, and Patnaik, Mrinal M., additional

Published
2018
Full Text
View/download PDF

12. Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series

Author

Yui, Jennifer, primary, Mudireddy, Mythri, additional, Patnaik, Mrinal M, additional, Gangat, Naseema, additional, Al-Kali, Aref, additional, Elliott, Michelle, additional, Hogan, William J., additional, Hook, C. Christopher, additional, Wolanskyj, Alexandra P, additional, Litzow, Mark R., additional, Howard, Matthew T, additional, Hanson, Curtis A., additional, Ketterling, Rhett P., additional, Pardanani, Animesh D., additional, Tefferi, Ayalew, additional, and Begna, Kebede H., additional

Published
2016
Full Text
View/download PDF

17. A Phase 1 Trial of Imatinib Mesylate with Daunorubicin and Cytarabine for Patients with C-Kit Positive Relapsed AML.

Author

Advani, Anjali, primary, Copelan, Edward A., additional, Sobecks, Ronald, additional, Sekeres, Mikkael A, additional, Bates, Jennifer, additional, Rush, Mary Lynn, additional, Tripp, Barbara, additional, Noon, Elysa, additional, Howard, Matthew, additional, Jin, Tao, additional, Hsi, Eric, additional, and Kalaycio, Matt, additional

Published
2008
Full Text
View/download PDF

19. Cell-Type and Allele Specific Distribution of Multiple TET2Mutations in Two Patients with Chronic Myelomonocytic Leukemia (CMML)

Author

Lasho, Terra, Finke, Christy, Timm, Michael M., Durruthy-Durruthy, Robert, Arribas-Layton, Marc, Patnaik, Mrinal M., Tefferi, Ayalew, Gangat, Naseema, Mangaonkar, Abhishek A., Binder, Moritz, Gaspar Maia, Alexandre, Mohammed Ismail, Wazim, Howard, Matthew T, and Chia, Nicholas

Abstract

Background: Chronic myelomonocytic leukemia (CMML) is an aging disease that arises on the background of clonal hematopoiesis, commonly involving multiple TET2mutations or TET2/SRSF2co-mutations. In a prior study of 1084 CMML patients (Leukemia 2020; 34:1407-1421), we demonstrated a high prevalence of TET2mutations (56%) in CMML, with approximately 30% of patients having >1 TET2mutation. The cell-type and allele specific distribution of these mutations remains of great interest and are thus far poorly defined. To visualize the genotypic and immunophenotypic correlates, we performed single-cell DNA analysis and simultaneous protein profiling on 2 CMML patients with multiple TET2mutations.

Published
2021
Full Text
View/download PDF

20. Differential Prognostic Impact of IDH1and IDH2Mutations in Chronic Myelomonocytic Leukemia

Author

Walsh, Connor M., Hunter, Anthony, Lasho, Terra, Finke, Christy, Komrokji, Rami S., Shah, Mithun V., Tefferi, Ayalew, Mangaonkar, Abhishek A., Howard, Matthew T, Gangat, Naseema, Al-Kali, Aref, Al Ali, Najla, Padron, Eric, and Patnaik, Mrinal M.

Abstract

Introduction: Mutations involving isocitrate dehydrogenase 1/2 (IDH) are known oncogenic drivers in hematological malignancies, conferring neomorphic enzymatic activity to IDH 1/2, resulting in the oncometabolite, 2-hydroxyglutarae (2-HG). 2-HG in turn suppresses TET activity, making IDHand TET2mutations synthetically lethal and almost mutually exclusive. The frequency of IDHmutations in CMML is <10% and their prognostic impact remains unclear. We carried out this study in a large database of molecularly annotated CMML patients to better define the clinical profile and prognostic impact of these mutations.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results